A prespecified subgroup analysis of a 44-week open-label extension study is presented. The efficacy and safety of the combination of amlodipine (AML)+ olmesartan medoxomil (OM), with and without the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results